Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Chi Zhang, Zhao Wu, Jiawen Li, Hong Zhao, Gui-Qiang Wang
Topics & Concepts
TocilizumabCytokine stormCytokine release syndromeMedicinePneumoniaCytokineInterleukin 1 receptor antagonistInterleukin 6Viral pneumoniaReceptor antagonistCase fatality rateImmunologyCoronavirus disease 2019 (COVID-19)Glycoprotein 130ReceptorInternal medicineDiseaseAntagonistRheumatoid arthritisInfectious disease (medical specialty)EpidemiologyLong-Term Effects of COVID-19COVID-19 Clinical Research StudiesInflammasome and immune disorders